These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23643633)

  • 1. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats.
    Cha JJ; Kang YS; Hyun YY; Han SY; Jee YH; Han KH; Han JY; Cha DR
    Life Sci; 2013 Jun; 92(23):1118-24. PubMed ID: 23643633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats.
    Cha DR; Kang YS; Han SY; Jee YH; Han KH; Han JY; Kim YS; Kim NH
    J Endocrinol; 2004 Oct; 183(1):183-94. PubMed ID: 15525586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property.
    Nam SM; Lee MY; Koh JH; Park JH; Shin JY; Shin YG; Koh SB; Lee EY; Chung CH
    Diabetes Res Clin Pract; 2009 Feb; 83(2):176-82. PubMed ID: 19111363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats.
    Lee MY; Lee EY; Lee BJ; Won CS; Koh JH; Shin JY; Shin YG; Cho BP; Chung CH
    Yonsei Med J; 2007 Apr; 48(2):301-7. PubMed ID: 17461531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal renal structural alterations during the development of diabetes mellitus in Otsuka Long-Evans Tokushima Fatty rats.
    Koike T; Tomoda F; Kinuno H; Inoue H; Takata M
    Acta Physiol Scand; 2005 May; 184(1):73-81. PubMed ID: 15847646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renal protective effects of sulodexide in diabetic rats and its anti-oxidative mechanism].
    Shu J; Zeng LY; Lin KY; Mu PW; Zhang GC; Chen YM; Wang MM
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):778-80. PubMed ID: 19403420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.
    Lee EY; Kim GT; Hyun M; Kim S; Seok S; Choi R; Lee MY; Chung CH
    Nephrol Dial Transplant; 2012 Nov; 27(11):4069-79. PubMed ID: 22892126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats.
    Ogawa M; Hirawa N; Tsuchida T; Eguchi N; Kawabata Y; Numabe A; Negoro H; Hakamada-Taguchi R; Seiki K; Umemura S; Urade Y; Uehara Y
    Nephrol Dial Transplant; 2006 Apr; 21(4):924-34. PubMed ID: 16384826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
    Schrijvers BF; De Vriese AS; Tilton RG; Van de Voorde J; Denner L; Lameire NH; Flyvbjerg A
    Horm Metab Res; 2005 Jan; 37(1):21-5. PubMed ID: 15702434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of heat-processed ginseng and its active component ginsenoside 20(S)-Rg3 on the progression of renal damage and dysfunction in type 2 diabetic Otsuka Long-Evans Tokushima Fatty rats.
    Kang KS; Yamabe N; Kim HY; Park JH; Yokozawa T
    Biol Pharm Bull; 2010; 33(6):1077-81. PubMed ID: 20522983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
    Lambers Heerspink HJ; Fowler MJ; Volgi J; Reutens AT; Klein I; Herskovits TA; Packham DK; Fraser IR; Schwartz SL; Abaterusso C; Lewis J;
    Diabet Med; 2007 Nov; 24(11):1290-5. PubMed ID: 17956455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.
    Schrijvers BF; Flyvbjerg A; Tilton RG; Lameire NH; De Vriese AS
    Nephrol Dial Transplant; 2006 Feb; 21(2):324-9. PubMed ID: 16249198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of the Chinese prescription Hachimi-jio-gan against renal damage in the Otsuka Long-Evans Tokushima fatty rat: a model of human type 2 diabetes mellitus.
    Yamabe N; Yokozawa T
    J Pharm Pharmacol; 2006 Apr; 58(4):535-45. PubMed ID: 16597372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria.
    Yongwatana K; Supasyndh O; Satirapoj B
    J Diabetes Res; 2020; 2020():2984680. PubMed ID: 32851094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients.
    Sulikowska B; Olejniczak H; Muszyńska M; Odrowaz-Sypniewska G; Gaddi A; Savini C; Cicero AF; Laghi L; Manitius J
    Am J Nephrol; 2006; 26(6):621-8. PubMed ID: 17191008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferulic acid prevents pathological and functional abnormalities of the kidney in Otsuka Long-Evans Tokushima Fatty diabetic rats.
    Fujita A; Sasaki H; Doi A; Okamoto K; Matsuno S; Furuta H; Nishi M; Nakao T; Tsuno T; Taniguchi H; Nanjo K
    Diabetes Res Clin Pract; 2008 Jan; 79(1):11-7. PubMed ID: 17897750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats.
    Li C; Yang CW; Park CW; Ahn HJ; Kim WY; Yoon KH; Suh SH; Lim SW; Cha JH; Kim YS; Kim J; Chang YS; Bang BK
    Kidney Int; 2003 Feb; 63(2):454-63. PubMed ID: 12631111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195.
    Tsuchida K; Makita Z; Yamagishi S; Atsumi T; Miyoshi H; Obara S; Ishida M; Ishikawa S; Yasumura K; Koike T
    Diabetologia; 1999 May; 42(5):579-88. PubMed ID: 10333051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.